[1]
|
Soupir, C.P., Vergilio, J.A., Cin, P.D., et al. (2007) Philadelphia chromosome-positive acute myeloid leukemia: A rare aggressive leukemia with clinicopathologic features distinct from chronic myeloid leukemia in myeloid blast crisis. American Journal of Clinical Pathology, 127, 642-650. doi:10.1309/B4NVER1AJJ84CTUU
|
[2]
|
Jentsch-Ullrich, K., Pelz, A.F., Braun, H., et al. (2004) Complete molecular remission in a patient with Philadelphia-chromosome positive acute myeloid leukemia after conventional therapy and imatinib. Haematologica, 89, ECR15.
|
[3]
|
Yamaguchi, M. and Konishi, I. (2003) Successful treatment with imatinib mesylate for Philadelphia chromosome-positive refractory acute myeloid leukemia]. Rinsho Ketsueki, 44, 254-6.
|
[4]
|
Leis, J.F., Stepan, D.E., Curtin, P.T., et al. (2001) Low penetration of imatinib (STI571) into the CSF indicates the need for standard CNS prophylaxis in patients with CML lymphoid blast crisis and Philadelphia chromosome positive ALL. Blood, 98, 140.
|
[5]
|
Pfeifer, H., Wassmann, B., Hofmann, W.-K., et al. (2003) Risk and prognosis of central nervous system leukemia in patients with Philadelphia chromosome-positive acute leukemias treated with imatinib mesylate. Clinical Cancer Research, 9, 4674-4681.
|
[6]
|
Takayama, N., Sato, N., O’Brien, S.G., et al. (2002) Imatinib mesylate has limited activity against the central nervous system involvement of Philadelphia chromosome-positive acute lymphoblastic leukemia due to poor penetration into cerebrospinal fluid. British Journal of Haematology, 119, 106-108.
doi:10.1046/j.1365-2141.2002.03881.x
|
[7]
|
Kondoa, T., Tasakab, T., Sanoa, F., et al. (2009) Philadelphia chromosome-positive acute myeloid leukemia (Ph + AML) treated with imatinib mesylate (IM): A report with IM plasma concentration and bcr-abl transcripts. Leukemia Research, 33, e137-e138.
doi:10.1016/j.leukres.2009.03.017
|
[8]
|
Helenglass, G., Testa, J.R. and Schiffer, C.A. (1987) Philadelphia chromosome-positive acute leukemia: Morphologic and clinical correlations. American Journal of Hematology, 25, 311-324. doi:10.1002/ajh.2830250311
|
[9]
|
van Dongen, J.J.M., Macintyre, E.A., Gabert, J.A., et al. (1999) Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: Investigation of minimal residual disease in acute leukemia. Leukemia, 13, 1901-1928. doi:10.1038/sj.leu.2401592
|
[10]
|
Petzer, A.L., Gunsilius, E., Hayes, M., et al. (2002) Low concentrations of STI571 in the cerebrospinal fluid: A case report. British Journal of Haematology, 117, 623-625. doi:10.1046/j.1365-2141.2002.03523.x
|
[11]
|
Dai, H., Marbach, P., Lemaire, M., et al. (2003) Distribution of STI-571 to the brain is limited by p-glycoprotein-mediated efflux. Journal of Pharmacology and Experimental Therapeutics, 304, 1085-1092.
doi:10.1124/jpet.102.045260
|
[12]
|
Patel, S.B., Gojo, I., Tidwell, M.L., Sausville, E.A., et al. (2011) Subdural hematomas in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving imatinib mesylate in conjunction with systemic and intrathecal chemotherapy. Leuk Lymphoma, 52, 1211-1214. doi:10.3109/10428194.2011.566950
|